Current Research on the Role of Histidine-rich glycoprotein (HRG) in Neovascularization

Xiaohan Pan; Wei Tan

doi:10.54097/dwbvfg30

Authors

Xiaohan Pan
Wei Tan

DOI:

https://doi.org/10.54097/dwbvfg30

Keywords:

Histidine-Rich Glycoprotein (HRG), Angiogenesis, Anti-angiogenesis

Abstract

Angiogenesis is a critical mechanism for blood vessel formation in both physiological and pathological processes, regulated by multiple cytokines and signaling pathways. In recent years, histidine-rich glycoprotein (HRG), a multifunctional plasma protein, has garnered increasing attention for its role in angiogenesis. This review summarizes the structural characteristics of HRG, its mechanisms of action, and functional manifestations in angiogenesis, and explores its potential as a therapeutic target, thereby opening new avenues for overcoming anti-angiogenic therapy resistance and improving drug delivery.

Downloads

Download data is not yet available.

References

[1] LEE C, BONGCAM-RUDLOFF E, SOLLNER C, et al. Type 3 cystatins; fetuins, kininogen, and histidine-rich glycoprotein [J]. Front Biosci (Landmark Ed), 2009, 14(8): 2911-22.

[2] DVORAK H F. Angiogenesis: update 2005 [J]. J Thromb Haemost, 2005, 3(8): 1835-42.

[3] RISAU W. Mechanisms of angiogenesis [J]. Nature, 1997, 386(6626): 671-4.

[4] CARMELIET P. Angiogenesis in life, disease and medicine [J]. Nature, 2005, 438(7070): 932-6.

[5] ROGUIN A, LEVY A P. Angiogenesis--an update [J]. Pediatr Endocrinol Rev, 2005, 2(3): 391-8.

[6] SANCHO M, KLUG N R, MUGHAL A, et al. Adenosine signaling activates ATP-sensitive K(+) channels in endothelial cells and pericytes in CNS capillaries [J]. Sci Signal, 2022, 15(727): eabl5405.

[7] POON I K, PATEL K K, DAVIS D S, et al. Histidine-rich glycoprotein: the Swiss Army knife of mammalian plasma [J]. Blood, 2011, 117(7): 2093-101.

[8] PAN Y, DENG L, WANG H, et al. Histidine-rich glycoprotein (HRGP): Pleiotropic and paradoxical effects on macrophage, tumor microenvironment, angiogenesis, and other physiological and pathological processes [J]. Genes Dis, 2020, 9(2): 381-92.

[9] OLSSON A K, LARSSON H, DIXELIUS J, et al. A fragment of histidine-rich glycoprotein is a potent inhibitor of tumor vascularization [J]. Cancer Res, 2004, 64(2): 599-605.

[10] SIMANTOV R, FEBBRAIO M, CROMBIE R, et al. Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1 [J]. J Clin Invest, 2001, 107(1): 45-52.

[11] JONES A L, HULETT M D, PARISH C R. Histidine-rich glycoprotein binds to cell-surface heparan sulfate via its N-terminal domain following Zn2+ chelation [J]. J Biol Chem, 2004, 279(29): 30114-22.

[12] SOBCZAK A I S, AJJAN R A, STEWART A J. Zn(2+) Differentially Influences the Neutralisation of Heparins by HRG, Fibrinogen, and Fibronectin [J]. Int J Mol Sci, 2023, 24(23).

[13] FOGLIA B, SUTTI S, CANNITO S, et al. Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis [J]. Front Immunol, 2024, 15: 1342404.

[14] BLANK M, SHOENFELD Y. Histidine-rich glycoprotein modulation of immune/autoimmune, vascular, and coagulation systems [J]. Clin Rev Allergy Immunol, 2008, 34(3): 307-12.

[15] KLENOTIC P A, HUANG P, PALOMO J, et al. Histidine-rich glycoprotein modulates the anti-angiogenic effects of vasculostatin [J]. Am J Pathol, 2010, 176(4): 2039-50.

[16] VANWILDEMEERSCH M, OLSSON A K, GOTTFRIDSSON E, et al. The anti-angiogenic His/Pro-rich fragment of histidine-rich glycoprotein binds to endothelial cell heparan sulfate in a Zn2+-dependent manner [J]. J Biol Chem, 2006, 281(15): 10298-304.

[17] MORI S, SHINOHATA R, RENBUTSU M, et al. Histidine-rich glycoprotein plus zinc reverses growth inhibition of vascular smooth muscle cells by heparin [J]. Cell Tissue Res, 2003, 312(3): 353-9.

[18] ZHONG H, WAKE H, LIU K, et al. Effects of Histidine-rich glycoprotein on erythrocyte aggregation and hemolysis: Implications for a role under septic conditions [J]. J Pharmacol Sci, 2018, 136(3): 97-106.

[19] LV K, CHEN S, XU X, et al. Protein disulfide isomerase cleaves allosteric disulfides in histidine-rich glycoprotein to regulate thrombosis [J]. Nat Commun, 2024, 15(1): 3129.

[20] GAO S, NISHIBORI M. Multiple Roles of Histidine-Rich Glycoprotein in Vascular Homeostasis and Angiogenesis [J]. Acta Med Okayama, 2021, 75(6): 671-5.

[21] GUAN X, JUAREZ J C, QI X, et al. Histidine-proline rich glycoprotein (HPRG) binds and transduces anti-angiogenic signals through cell surface tropomyosin on endothelial cells [J]. Thromb Haemost, 2004, 92(2): 403-12.

[22] MUKO R, SUNOUCHI T, URAYAMA S, et al. Unique insertion/deletion polymorphisms within histidine-rich region of histidine-rich glycoprotein in Thoroughbred horses [J]. Sci Rep, 2023, 13(1): 300.

[23] JUAREZ J C, GUAN X, SHIPULINA N V, et al. Histidine-proline-rich glycoprotein has potent antiangiogenic activity mediated through the histidine-proline-rich domain [J]. Cancer Res, 2002, 62(18): 5344-50.

[24] DOñATE F, JUAREZ J C, GUAN X, et al. Peptides derived from the histidine-proline domain of the histidine-proline-rich glycoprotein bind to tropomyosin and have antiangiogenic and antitumor activities [J]. Cancer Res, 2004, 64(16): 5812-7.

[25] KAUR B, BRAT D J, DEVI N S, et al. Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor [J]. Oncogene, 2005, 24(22): 3632-42.

[26] THEEK B, BAUES M, GREMSE F, et al. Histidine-rich glycoprotein-induced vascular normalization improves EPR-mediated drug targeting to and into tumors [J]. J Control Release, 2018, 282: 25-34.

[27] TUGUES S, ROCHE F, NOGUER O, et al. Histidine-rich glycoprotein uptake and turnover is mediated by mononuclear phagocytes [J]. PLoS One, 2014, 9(9): e107483.

[28] IRUELA-ARISPE M L, LOMBARDO M, KRUTZSCH H C, et al. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats [J]. Circulation, 1999, 100(13): 1423-31.

[29] SIMANTOV R, FEBBRAIO M, SILVERSTEIN R L. The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein [J]. Matrix Biol, 2004, 24(1): 27-34.

[30] STREIT M, RICCARDI L, VELASCO P, et al. Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis [J]. Proc Natl Acad Sci U S A, 1999, 96(26): 14888-93.

[31] JIMéNEZ B, VOLPERT O V, CRAWFORD S E, et al. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1 [J]. Nat Med, 2000, 6(1): 41-8.

[32] FRAZIER W A. Thrombospondin: a modular adhesive glycoprotein of platelets and nucleated cells [J]. J Cell Biol, 1987, 105(2): 625-32.

[33] QIN Y, ZHANG J, BABAPOOR-FARROKHRAN S, et al. PAI-1 is a vascular cell-specific HIF-2-dependent angiogenic factor that promotes retinal neovascularization in diabetic patients [J]. Sci Adv, 2022, 8(9): eabm1896.

[34] FEBBRAIO M, HAJJAR D P, SILVERSTEIN R L. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism [J]. J Clin Invest, 2001, 108(6): 785-91.

[35] CHENG X, ZHANG X, CHENG W, et al. Tumor-specific delivery of histidine-rich glycoprotein suppresses tumor growth and metastasis by anti-angiogenesis and vessel normalization [J]. Curr Gene Ther, 2014, 14(2): 75-85.

[36] AKSORNPHUSITAPHONG A, PHUPONG V. Combination of serum histidine-rich glycoprotein and uterine artery Doppler to predict preeclampsia [J]. Hypertens Res, 2018, 41(4): 275-81.

[37] BORNSTEIN P. Thrombospondins as matricellular modulators of cell function [J]. J Clin Invest, 2001, 107(8): 929-34.

[38] SHIMADA K, KAWAMOTO A, MATSUBAYASHI K, et al. Histidine-rich glycoprotein does not interfere with interactions between antithrombin III and heparin-like compounds on vascular endothelial cells [J]. Blood, 1989, 73(1): 191-3.

[39] PETRIK J, LAUKS S, GARLISI B, et al. Thrombospondins in the tumor microenvironment [J]. Semin Cell Dev Biol, 2024, 155(Pt B): 3-11.